http://rdf.ncbi.nlm.nih.gov/pubchem/patent/MY-169532-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_96ec3985e3ce9b24614fb87bf51a4f12 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-635 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57415 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-517 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-436 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377 |
| filingDate | 2012-03-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_32f65874f3dcca5ef4b8204afda04f0f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2fd73b265c03fc1e0e8562a81f1bd445 |
| publicationDate | 2019-04-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | MY-169532-A |
| titleOfInvention | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines |
| abstract | The present invention relates to: -tuse of a 2,3-dihydroimidazo[1,2-c]quinazoline compound, or of a pharmaceutical composition containing same, as a sole active agent, or of a combination of a) said compound or a pharmaceutical composition containing said compound and b) one or more further active agents, for the preparation of a medicament for the treatment or prophylaxis of cancer ; -tcombinations of a) said compound and b) one or more further active agents ; -ta pharmaceutical composition comprising said compound as a sole active agent for the treatment of breast cancer ; -ta pharmaceutical composition comprising a combination of a) said compound and b) one or more further active agents ; -tuse of biomarkers involved in the modification of Bcl expression, HER family expression and/or activation, PIK3CA signaling and/ or loss of PTEN for predicting the sensitivity and/or resistance of a cancer patient to said compound and providing a rationale-based synergistic combination as defined herein to increase sensitivity and/or to overcome resistance ; and -ta method of determining the level of a component of one or more of Bcl expression, HER family expression and/or activation, PIK3CA signaling and/ or loss of PTEN. |
| priorityDate | 2011-04-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 33.